Similar Posts
True Stories of the Challenges of Neurological Conditions and Bladder and Bowel Programs – Laurie’s Story
Laurie’s Story December 14, 2005, started out like every other workday. I needed to get dressed, but decided to fix my coffee first and that is when I realized something was different. I was stirring my coffee and both my feet began to tingle as if they were asleep. I tried stomping my feet on…
Restoring Voluntary Bladder & Bowel Control for the Spinal Cord Injured – How You Can Help
About Current Bladder and Bowel Programs Thank you for your interest in Dignify Therapeutics’ journey to restore voluntary control of bodily functions to people with spinal cord conditions such as paraplegia, spina bifida, and multiple sclerosis. For many with these conditions, restoring control over their bladder and bowel is just as important as gaining mobility. The current…
Dignify Therapeutics Advances into Clinic with FDA Clearance of IND for DTI-117 in Neurogenic Bowel Dysfunction
ByjwelchNIH-funded randomized, double-blind, placebo-controlled Phase 1 single-ascending-dose study expected to begin dosing healthy volunteers in November 2026 Preliminary topline data from initial cohorts anticipated in early 2027 RESEARCH TRIANGLE PARK, N.C., Oct. 7, 2026 /PRNewswire/ — Dignify Therapeutics (“Dignify”, the “Company”), a biopharmaceutical development company focused on restoring bowel and bladder control for people with…
Dignify Therapeutics awarded two new research grants from the National Institutes of Health (NIH)
RESEARCH TRIANGLE PARK, NC (September 19, 2024) – Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, recently received two significant research grants from the NIH. These grants add to the previous $20 million in research funding the company has received to advance multiple therapeutics for bladder and bowel disorders. Grants…
Dignify Therapeutics Selected as a Praxis SCI Accelerate Company
ByjwelchCompany RESEARCH TRIANGLE PARK, NC (October 22, 2024) – Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, has been selected as a participating company in the Praxis Spinal Cord Injury (SCI) Accelerate Program. SCI Accelerate is a commercialization program ‘geared towards healthcare companies with a product ready to launch into…
Dignify Therapeutics’ Chief Scientific Officer invited to participate at CURE-UAB
Dignify Therapeutics’ Chief Scientific Officer, Karl B. Thor, PhD, has been invited to participate as a Faculty member at the 2nd International Congress on Underactive Bladder – CURE-UAB in Denver, CO, Dec. 3-4, 2015. His presentation is entitled “Pharmaceutical Targets for Drug-induced Voiding”. This NIH-sponsored congress brings together academic, pharmaceutical, and medical device experts to…

